Oxaliplatin-induced immune mediated thrombocytopenia

Muhammad S. Beg, Rami S. Komrokji, Kashif Ahmed, Malek M. Safa

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.

Original languageEnglish (US)
Pages (from-to)925-927
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Issue number5
StatePublished - Oct 1 2008


  • Immune
  • Oxaliplatin
  • Thrombocytopenia

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Oxaliplatin-induced immune mediated thrombocytopenia'. Together they form a unique fingerprint.

Cite this